Kiniksa Pharmaceuticals International (KNSA) Other Accumulated Expenses (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Other Accumulated Expenses for 10 years, with the latest figure at $20.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 4757.04% year-over-year to $20.7 million; the trailing twelve-month figure through Mar 2026 stood at $20.7 million (up 4757.04% YoY), and the FY2025 full-year result was $598000.0, down 96.49% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $20.7 million, up from $598000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $22.2 million in Q1 2022, with the low at $111000.0 in Q2 2024.
• Historically, Other Accumulated Expenses has averaged $6.1 million across 5 years, with a median of $2.9 million in 2023.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 7532.99% — and 2025, when it slumped 96.49%.
• Kiniksa Pharmaceuticals International's Other Accumulated Expenses stood at $5.8 million in 2022, then soared by 42.39% to $8.2 million in 2023, then soared by 108.06% to $17.0 million in 2024, then tumbled by 96.49% to $598000.0 in 2025, then surged by 3360.03% to $20.7 million in 2026.
• The last three Other Accumulated Expenses figures came in at $20.7 million (Q1 2026), $598000.0 (Q4 2025), and $9.0 million (Q3 2025), per Business Quant data.